A Phase 3 interventional study of Vonicog Alfa and ADVATE in Von Willebrand Disease (VWD), sponsored by Takeda. Recruiting at 23 sites in 6 countries. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2026-09-09.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in von Willebrand Diseases by Takeda — 3 open to participants now, 3 under way, 2 of them phase 3. von Willebrand Diseases · Takeda.
Among the 13 studies in von Willebrand Diseases by Takeda, this one is the only one that started in 2024, is one of 7 in phase 3, and was the 8th registered.
96 studies on the registry are indexed under von Willebrand Diseases; 25 are open to participants now.
Browse von Willebrand Diseases studies →3 of the 13 studies in von Willebrand Diseases by Takeda are open now, in 7 countries. Recruiting first, the newest first:
Takeda · Sites in Japan
Ages up to 17
Takeda · Sites in China
Ages 18+
By country, each count listing its studies:
Of the 23 von Willebrand Diseases studies recruiting now, 15 (65%) set no upper age limit and 8 (35%) stop at 75 or younger; 14 take children under 18; 3 take healthy volunteers.
This study: Up to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2024.
This study's planned enrollment of 24 is close to the median of 25 across 41 interventional studies indexed under von Willebrand Diseases.
Median enrollment 31 across the 8 interventional studies, 24 across the 4 observational. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
1 of the studies in von Willebrand Diseases by Takeda that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07129343Phase 3TakedaA Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD) | 2027-11-25 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in von Willebrand Diseases by Takeda, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main aim of the study is to evaluate the effectiveness of prophylaxis with vonicog alfa (recombinant von Willebrand factor [rVWF]) in children. This study will enroll those participants who have been previously treated with VWF product or with a plasma-derived VWF (pdVWF) product. In this study, participants will be treated with vonicog alfa (rVWF) for 12 months.
During the study, participants will visit the study clinic 5 times after treatment initiation.
Prescreening treatment requirements:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with age greater than or equal to (\>=) 12 to less than (\<) 18 years who have received on-demand (OD) therapy or prophylactic treatment with a pdVWF product will receive vonicog alfa (rVWF) with an initial dose selected within the range of 40 to 60 international units per kilogram (IU/kg) vonicog alfa (rVWF), intravenous infusions, twice-weekly for 12 months. Participants may receive vonicog alfa (rVWF) with or without ADVATE intravenous infusions, when indicated (as deemed necessary for breakthrough bleeding episode treatment and perioperative bleeding management).
Biological: Vonicog Alfa · Biological: ADVATE
Participants with age \>=6 to \<12 years who have received OD therapy of VWF product or prophylactic treatment with a pdVWF product will receive vonicog alfa (rVWF) with an initial dose selected within the range of 40 to 60 IU/kg vonicog alfa (rVWF), intravenous infusions, twice-weekly for 12 months. Participants may receive vonicog alfa (rVWF) with or without ADVATE intravenous infusions, when indicated (as deemed necessary for breakthrough bleeding episode treatment and perioperative bleeding management).
Biological: Vonicog Alfa · Biological: ADVATE
Participants with age \<6 years who have received OD therapy of VWF product or prophylactic treatment with a pdVWF product will receive vonicog alfa (rVWF) with an initial dose selected within the range of 40 to 60 IU/kg vonicog alfa (rVWF), intravenous infusions, twice-weekly for 12 months. Participants may receive vonicog alfa (rVWF) with or without ADVATE intravenous infusions, when indicated (as deemed necessary for breakthrough bleeding episode treatment and perioperative bleeding management).
Biological: Vonicog Alfa · Biological: ADVATE
Vonicog Alfa administered by intravenous injection.
Also known as: TAK-577, Recombinant von Willebrand Factor (rVWF), Vonvendi-Veyvondi
ADVATE administered by intravenous injection.
Also known as: Recombinant Factor VIII (rFVIII), Octocog Alfa
Annualized Bleeding Rate (ABR) for Spontaneous or Traumatic Bleeding Episodes as Assessed by Investigator During Prophylactic Treatment With Vonicog Alfa (rVWF)
ABR during the study compared to historical ABR for each participant for both spontaneous and traumatic bleeding episodes as classified by the investigator during prophylactic treatment with vonicog alfa (rVWF) will be reported.
Time frame: 12 months
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Number of participants with TEAEs and SAEs will be reported.
Time frame: 12 months
Number of Participants With TEAEs by Severity
Number of participants with severity of TEAE will be reported.
Time frame: 12 months
Number of Participants With TEAEs and SAEs by Causality
Number of participants with causality related TEAEs and SAEs will be reported.
Time frame: 12 months
Number of Participants With Thromboembolic Events, Hypersensitivity Reactions and Infusion-Related Reactions (IRR)
Number of participants with thromboembolic events, hypersensitivity reactions and IRR will be reported.
Time frame: 12 months
Number of Participants Who Develop Neutralizing Antibodies to VWF and Factor VIII (FVIII)
Number of participants who develop neutralizing antibodies to VWF and FVIII will be reported.
Time frame: 12 months
Number of Participants Who Develop Binding Antibodies to VWF and FVIII
Number of participants who develop total binding antibodies to VWF and FVIII will be reported.
Time frame: 12 months
Number of Participants With Clinically Significant Change From Baseline Values in Vital Sign Parameters
Number of participants with clinically significant change from baseline values in vital sign parameters per investigator assessment will be reported.
Time frame: 12 months
Number of Participants With Clinically Significant Change From Baseline Values in Laboratory Parameters
Number of participants with clinically significant change from baseline values in laboratory parameters per investigator assessment will be reported.
Time frame: 12 months
Number of Participants With Categorized ABR
ABR categorized as 0, 0-2, 2-5, or \>5 bleeding episodes during vonicog alfa (rVWF) prophylaxis. Number of participants with categorized ABR will be reported.
Time frame: 12 months
Number of Participants Previously Receiving On-demand Treatment who will Achieve ABR Percent Reduction Success
ABR percent reduction success is defined as at least 25% reduction of ABR during vonicog alfa (rVWF) prophylaxis relative to the participant's own historical ABR during OD treatment prior to enrollment in this study. Number of participants previously receiving on-demand treatment who will achieve ABR percent reduction success will be reported.
Time frame: 12 months
Number of pdVWF Switch Participants With Spontaneous ABR Preservation Success
ABR preservation success is defined as achieving an ABR for spontaneous bleeding episodes during vonicog alfa (rVWF) prophylaxis that is no greater than the participant's own historical ABR during prophylactic treatment with pdVWF prior to enrollment in this study. Number of pdVWF switch participants with spontaneous ABR preservation success will be reported.
Time frame: 12 months
Number of Spontaneous ABR Historically and While on Prophylactic Treatment With Vonicog Alfa (rVWF) by Location of Bleeding
Number of spontaneous ABR historically and while on prophylactic treatment with vonicog alfa (rVWF) by location of bleeding will be reported.
Time frame: 12 months
ABR for Bleeding Episodes by Bleeding Cause Historically and While on Prophylactic Treatment With Vonicog Alfa (rVWF)
ABR for bleeding episodes by bleeding cause historically and while on prophylactic treatment with vonicog alfa (rVWF) will be reported.
Time frame: 12 months
Total Number of Infusions Administered Per Week During Prophylactic Treatment With Vonicog Alfa (rVWF)
Total number of infusions administered per week during prophylactic treatment with vonicog alfa (rVWF) will be reported.
Time frame: 12 months
Average Number of Infusions Per Week During Prophylactic Treatment With Vonicog Alfa (rVWF)
Average number of infusions per week during prophylactic treatment with vonicog alfa (rVWF) will be reported.
Time frame: 12 months
Total Weight Adjusted Consumption of Vonicog Alfa (rVWF) Per Month During Prophylactic Treatment
Total weight adjusted consumption of vonicog alfa (rVWF) per month during prophylactic treatment will be reported.
Time frame: 12 months
Overall Hemostatic Efficacy Rating of Breakthrough Bleed Treatment at Resolution of the Bleeding Episode
Overall hemostatic efficacy rating of breakthrough bleed treatment at resolution of the bleeding episode will be reported.
Time frame: 12 months
Number of Infusions of rVWF and ADVATE (rFVIII, octocog alfa) per Bleeding Episode
Number of infusions of vonicog alfa (rVWF) and ADVATE per bleeding episode will be reported.
Time frame: 12 months
Weight-adjusted Consumption of Vonicog Alfa (rVWF) and ADVATE per Bleeding Episode
Weight-adjusted consumption of vonicog alfa (rVWF) and ADVATE per bleeding episode will be reported.
Time frame: 12 months
Plasma Level of Vonicog Alfa (rVWF) based on Von Willebrand Factor: Ristocetin Cofactor (VWF:Rco)
Plasma level of vonicog alfa (rVWF) based on VWF:Rco will be reported.
Time frame: Within 30 minutes pre-infusion and at multiple timepoints (up to 96 hours) post-infusion
Plasma Level of Vonicog Alfa (rVWF) based on Von Willebrand Factor Antigen (VWF:Ag)
Plasma level of vonicog alfa (rVWF) based on VWF:Ag will be reported.
Time frame: Within 30 minutes pre-infusion and at multiple timepoints (up to 96 hours) post-infusion
Plasma Level of Vonicog alfa (rVWF) based on Von Willebrand Factor Collagen Binding (VWF:CB)
Plasma level of vonicog alfa (rVWF) based on VWF:CB will be reported.
Time frame: Within 30 minutes pre-infusion and at multiple timepoints (up to 96 hours) post-infusion
Plasma Level of Vonicog alfa (rVWF) based on Von Willebrand Factor Glycoprotein 1b Binding (VWF:GP1bM)
Plasma level of vonicog alfa (rVWF) based on VWF:GP1bM will be reported.
Time frame: Within 30 minutes pre-infusion and at multiple timepoints (up to 96 hours) post-infusion
Plasma Level of Factor VIII Clotting (FVIII:C)
Plasma level of FVIII:C will be reported.
Time frame: Within 30 minutes pre-infusion and at multiple timepoints (up to 96 hours) post-infusion
Incremental Recovery Based on VWF:Rco
Incremental recovery based on VWF:Rco will be reported.
Time frame: 12 months
Incremental Recovery Based on VWF:Ag
Incremental recovery based on VWF:Ag will be reported.
Time frame: 12 months
Incremental Recovery Based on VWF:CB
Incremental recovery based on VWF:CB will be reported.
Time frame: 12 months
Incremental Recovery Based on VWF:GP1bM
Incremental recovery based on VWF:GP1bM will be reported.
Time frame: 12 months
Ratio of Area Under the Plasma Level Versus Time Curve From Time 0 to End of the Partial Dosing Interval (AUC0- Tau;ss) and Area Under the Level Versus Time Curve From 0 to 96 Hours (AUC0-96; ss) for VWF:Rco
Ratio of AUC0- Tau;ss/AUC0-96; ss for VWF:Rco will be reported.
Time frame: Within 30 minutes pre-infusion and at multiple timepoints (up to 96 hours) post-infusion
Terminal Half-life (T1/2) for VWF:Rco
TT1/2 based on VWF:Rco will be reported.
Time frame: Within 30 minutes pre-infusion and at multiple timepoints (up to 96 hours) post-infusion
Maximum Plasma Level During the Partial Dosing Interval at Steady State (Cmax;ss) for VWF:Rco
Cmax;ss for VWF:Rco will be reported.
Time frame: Within 30 minutes pre-infusion and at multiple timepoints (up to 96 hours) post-infusion
Minimum Time to Reach the Maximum Plasma Level at Steady State (Tmax;ss) for VWF:Rco
Tmax;ss for VWF:Rco will be reported.
Time frame: Within 30 minutes pre-infusion and at multiple timepoints (up to 96 hours) post-infusion
Volume of Distribution at Steady State (Vss) for VWF:Rco
Vss for VWF:Rco will be reported.
Time frame: Within 30 minutes pre-infusion and at multiple timepoints (up to 96 hours) post-infusion
Clearance (CL) for VWF:Rco
CL for VWF:Rco will be reported.
Time frame: Within 30 minutes pre-infusion and at multiple timepoints (up to 96 hours) post-infusion
Maximum Plasma Level During the Partial Dosing Interval at Steady State (Cmax;ss) for FVIII:C
Cmax;ss for FVIII:C will be reported.
Time frame: Within 30 minutes pre-infusion and at multiple timepoints (up to 96 hours) post-infusion
Minimum Time to Reach the Maximum Plasma Level at Steady State (Tmax;ss) for FVIII:C
Tmax;ss for FVIII:C will be reported.
Time frame: Within 30 minutes pre-infusion and at multiple timepoints (up to 96 hours) post-infusion
Ratio of Area Under the Plasma Level Versus Time Curve From Time 0 to End of the Partial Dosing Interval (AUC0- Tau;ss) and Area Under the Level Versus Time Curve From 0 to 96 Hours (AUC0-96; ss) for FVIII:C
Ratio of AUC0- Tau;ss and AUC0-96; ss for FVIII:C will be reported.
Time frame: Within 30 minutes pre-infusion and at multiple timepoints (up to 96 hours) post-infusion
Area Under the Level Versus Time Curve From 0 to 96 Hours (AUC0-96; ss) for FVIII:C
AUC0-96; ss for FVIII:C will be reported.
Time frame: Within 30 minutes pre-infusion and at multiple timepoints (up to 96 hours) post-infusion
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/ For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Started Nov 2024 (actual). Primary completion is estimated for Apr 2030, 65 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vonicog alfa